AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00866645
Drug: Intramuscular Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
Trial: NCT00866645
Drug: Intramuscular Levosulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
Trial: NCT01843751
Drug: buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
Trial: NCT00301171
Drug: Inhaled Fluticasone
RxNorm normalized name: fluticasone Inhalant Product
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00503113
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg per oral (po) weekly
Trial: NCT00475917
Drug: XL844
RxNorm normalized name: XL844
DrugBank: XL844 (DB05149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
Trial: NCT00475917
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once-weekly 30-minute IV infusion
Trial: NCT03431337
Drug: Amoxicillin 875 mg
RxNorm normalized name: amoxicillin 875 MG
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
Trial: NCT01847222
Drug: Normal Saline Solution
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02999087
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
Trial: NCT02999087
Drug: avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
Trial: NCT02999087
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
Trial: NCT00458289
Drug: Lanthanum carbonate (chewed vs. crushed)
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
Trial: NCT04501094
Drug: Bintrafusp alfa (M7824)
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1200 mg administered intravenous (IV) every two weeks
Trial: NCT00476437
Drug: biphasic insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00476437
Drug: biphasic human insulin
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration 100 mg
Trial: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration 50 mg
Trial: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration 25 mg, 50mg
Trial: NCT01711827
Drug: Isavuconazole
RxNorm normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01711827
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration 25 mg
Trial: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering 50 mg, placebo
Trial: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering 50 mg, 25 mg
Trial: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering 50 mg QOD
Trial: NCT01230645
Drug: RV568
RxNorm normalized name: Ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
Trial: NCT00230594
Drug: desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
Trial: NCT00891072
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00891072
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03934827
Drug: MRx0518 Capsules
RxNorm normalized name: MRx0518
DrugBank: MRx0518 (DB17523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
Trial: NCT03934827
Drug: MRx0518/placebo Capsules
DrugBank: MRx0518 (DB17523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
Trial: NCT02809768
Drug: Avatrombopag
RxNorm normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02809768
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02809768
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02809768
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03361124
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of additional 20 mU Oxytocin
Trial: NCT01787110
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see arm description
Trial: NCT04920370
Drug: ALXN1720 SC
RxNorm normalized name: IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN SERUM ALBUMIN) (HUMAN-LAMA GLAMA MONOCLONAL ALXN1720 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (SYNTHETIC 15 AMINO-ACID) FUSION PROTEIN WITH ANTI-(HUMAN COMPLEMENT C5) (HUMAN-LAMA GLAMA MONOCLO
DrugBank: Gefurulimab (DB18928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1720 will be administered via SC route.
Trial: NCT00387517
Drug: Aliskiren/HCTZ
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04920370
Drug: ALXN1720 IV
RxNorm normalized name: IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN SERUM ALBUMIN) (HUMAN-LAMA GLAMA MONOCLONAL ALXN1720 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (SYNTHETIC 15 AMINO-ACID) FUSION PROTEIN WITH ANTI-(HUMAN COMPLEMENT C5) (HUMAN-LAMA GLAMA MONOCLO
DrugBank: Gefurulimab (DB18928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1720 will be administered via IV route.
Trial: NCT01134341
Drug: Pralatrexate Injection
RxNorm normalized name: pralatrexate Injection
DrugBank: Pralatrexate (DB06813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met.
Trial: NCT01134341
Drug: Bexarotene Capsules
RxNorm normalized name: Bexarotene Capsules
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met.
Trial: NCT01247740
Drug: compounded monobag
RxNorm normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: parenteral nutrition
Trial: NCT01374620
Drug: Paclitaxel dose escalation
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~* 40~* 60~* 70~* 75~* 80~* 85~* 90
Trial: NCT01374620
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
Trial: NCT00664287
Drug: niacin (+) laropiprant
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
Trial: NCT00114595
Drug: eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02333188
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
RxNorm normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02333188
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00705315
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
Trial: NCT00705315
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
Trial: NCT00705315
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
Trial: NCT02809456
Drug: Nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral intake
Trial: NCT00784979
Drug: CMVIG
RxNorm normalized name: CMVIG
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
Trial: NCT02812771
Drug: Efinaconazole
RxNorm normalized name: Efinaconazole
DrugBank: Efinaconazole (DB09040)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution
Trial: NCT00864799
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
Trial: NCT02451306
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See information in arm description.
Trial: NCT01959490
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01959490
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01959490
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01959490
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04500132
Drug: EC-18
RxNorm normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-18 QD
Trial: NCT00683787
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV once every 3 weeks
Trial: NCT00683787
Drug: vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vandetanib once daily
Trial: NCT02625506
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
Trial: NCT02625506
Drug: Levobupivacaine and Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
Trial: NCT01651585
Drug: Valacyclovir arrow
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
Trial: NCT01288391
Drug: NNC 0128-0000-2011
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
Trial: NCT01288391
Drug: NNC 0128-0000-2011
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
Trial: NCT02849236
Drug: Ropivacaine (PECS bloc)
RxNorm normalized name: Gold-Bloc
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles
Trial: NCT02124902
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02124902
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00183196
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
Trial: NCT00183196
Drug: Naltrexone plus Gabapentin
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
Trial: NCT01170507
Drug: vitamin D3 1000 IU orally daily for 5 months
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01170507
Drug: vitamin D3 3000 IU orally daily for 5 months
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01170507
Drug: vitamin D3 5000 IU orally daily for 5 months
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01434069
Drug: SOM230C LAR
RxNorm normalized name: pasireotide
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
Trial: NCT02246764
Drug: Timolol maleate Ophthalmic Solution 0.5% BID
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop BID, AM/PM, OU
Trial: NCT01434069
Drug: FOLFIRI Infusion
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard therapy of FOLFIRI
Trial: NCT02335294
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rescue: Ibuprofen, oxycodone
Trial: NCT00403949
Drug: Azelaic acid 15% gel
RxNorm normalized name: AZELAIC ACID 15% GEL,TOP
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gel, applied once daily, for 6 weeks
Trial: NCT00403949
Drug: Non-active base from azelaic acid 15% gel
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gel, apply once daily for six weeks
Trial: NCT03164837
Drug: 68Ga-NOTA-RM26
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
Trial: NCT03201978
Drug: GSK2894512 MATCHING VEHICLE CREAM
RxNorm normalized name: ACh
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
Trial: NCT03657238
Drug: RD01
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single S.C. dose of RD01 for subjects in test group
Trial: NCT00426530
Drug: everolimus (RAD001)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00894842
Drug: Pregnenolone
RxNorm normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
Trial: NCT00458419
Drug: naloxone versus placebo
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
Trial: NCT00458419
Drug: intravenous injection of normal saline or naloxone
RxNorm normalized name: Rosula NS Medicated Pad or Tape
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
Trial: NCT02347319
Drug: Pennel
RxNorm normalized name: Fennel
DrugBank: Fennel (DB15615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
Trial: NCT02347319
Drug: Legalon
DrugBank: Silibinin (DB09298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
Trial: NCT03844997
Drug: Palcociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).~Palbociclib will be supplied as capsules or tablets containing 125 mg equivalents of Palbociclib free base
Trial: NCT03844997
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
Trial: NCT01454440
Drug: Eptifibatide
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
Trial: NCT03843515
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant nivolumab flat dose 400mg